Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

DISEASE CHARACTERISTICS:

* Histologically confirmed diagnosis of one of the following:

  * Hodgkin or non-Hodgkin lymphoma (including small lymphocytic lymphoma \[SLL\])

    * Any histology, including B, T, or NK/T cell allowed
  * Multiple myeloma (MM)
* Relapsed or refractory disease

  * Patients with lymphoma must have relapsed after or be refractory to an upfront regimen (e.g., CHOP or ABVD) and a salvage regimen (e.g., ICE or ESHAP)

    * Patients with SLL should have relapsed after a fludarabine-containing regimen
  * Patients with MM must have progressed within 100 days after receiving a regimen containing bortezomib and either thalidomide or lenalidomide AND have a 25% increase in serum paraproteins, urinary light chains, or plasma cell number in the bone marrow
* No active CNS disease

PATIENT CHARACTERISTICS:

* ECOG performance status 0-2
* ANC ≥ 1,500/mm³
* Platelet count ≥ 75,000/mm³ (transfusion allowed in patients with biopsy-proven bone marrow involvement)
* AST and ALT ≤ 2.5 times upper limit of normal (ULN) (≤ 5.0 times ULN if elevation due to leukemic involvement)
* Serum bilirubin ≤ 1.5 times ULN
* Serum creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 50 mL/min
* Serum potassium normal
* Serum phosphorous normal
* Serum total calcium (corrected for serum albumin) or serum ionized calcium normal
* Serum magnesium normal
* TSH and free T4 normal (thyroid hormone replacement allowed)
* Fasting serum cholesterol ≤ 300 mg/dL (or ≤ 7.75 mmol/L) AND fasting triglycerides ≤ 2.5 times ULN (elevated levels allowed provided an appropriate lipid-lowering medication has been initiated)
* LVEF normal by MUGA or ECHO
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective double-method (including barrier method) contraception during and for 3 months after completion of study treatment
* No impaired cardiac function, including any of the following:

  * QTc \> 450 msec by screening ECG
  * Congenital long QT syndrome
  * History of sustained ventricular tachycardia
  * History of ventricular fibrillation or torsades de pointes
  * Bradycardia, defined as heart rate (HR) \< 50 beats/min (pacemaker allowed provided HR ≥ 50 beats/min)
  * Myocardial infarction or unstable angina within the past 6 months
  * NYHA class III-IV congestive heart failure
  * Right bundle branch block and left anterior hemiblock (bifascicular block)
* No uncontrolled hypertension
* No unresolved diarrhea \> CTCAE grade 1
* No impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral agents (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
* No other concurrent severe or uncontrolled medical condition
* No other primary malignancy within the past 5 years other than curatively treated carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin
* No known HIV or hepatitis C positivity
* No significant history of non-compliance to medical regimens
* No known hypersensitivity to everolimus, other rapamycins (e.g., sirolimus or temsirolimus), or their excipients

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* Prior autologous or allogeneic stem cell transplantation allowed
* More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) or radiotherapy and recovered
* More than 1 week since prior and no concurrent immunization with live attenuated vaccines
* More than 4 weeks since prior valproic acid
* No other prior histone deacetylase inhibitors
* No concurrent chronic systemic corticosteroids or another immunosuppressive agent, other than for control of itching (as in cutaneous T-cell lymphoma)

  * Concurrent corticosteroids allowed provided patient has been on a stable dosage regimen for ≥ 2 weeks before study entry
  * Topical or inhaled corticosteroids allowed
* No concurrent drugs that may induce torsades de pointes
* No concurrent CYP3A4 inhibitors
* No concurrent radiotherapy or other anticancer therapy
* No concurrent grapefruit, grapefruit juice, or seville (sour) oranges
* No concurrent medications that may cause QTc prolongation
* No other concurrent investigational therapy